

Board of Directors (in Public)

Item: 5.1.2a
Subject: Integrated Performance Committee BAF Key Issues Report
Date of Meeting: 29th March 2023
Presented by: Louise Robson, Chair Integrated Performance Committee
Meeting Held: 27th February 2023

Agenda Item	Lead Exec	Assurance Received	New/ Emerging Risks	Actions/ Comments
5.1 Performance Report	JM	Operational Performance presentation outlining the key risks and mitigations	Continued focus on long waiters, Cancer and Admin. Anaesthetic sickness highlighted for Q4.	Significant risks associated with proposed industrial action
5.2 Activity and Industrial Action	JM	Presentation on the impact of industrial activity on activity and recovery.	Impact on Elective Services, Cancer pathways and diagnostics, RTT validation and pathway management.	Weekly Performance reviewed through both divisions and Trust performance meeting.
5.3 Long Waiters	JM	Presentation outlining position against trajectory. Issues arise in mini-mitral and ACHD Surgery due to specialist operators.	Industrial Action resulting in all non-emergency cardiac activity being cancelled. Some critical care capacity pressures also noted.	Monitoring of action plan and TCI management.
5.4 Cancer	JM	Presentation outlining position against cancer performance targets. Issues continue in Faster Diagnosis Target (FDS) and backlog due to industrial action pressures Q1 trajectory in place – with expected improvements in performance.	January performance significantly impacted by delays in due to Industrial Action in December 2022 and January 2023.	Diagnostic waiting times are being monitored and actions taken to reduce waiting times to support the recovery of the cancer position.
5.5 Administration	JM	Presentation outlining current risks and improvement plan progress.	Sickness impacting on typing performance. Increased administration burden to manage IA.	Action Plan in place with ongoing monitoring.
6.1 Operational Planning	JM	Operational priorities and planning guidance shared. Key objectives for LHCH	System financial and performance expectations being monitored and picked up through the annual	Refine activity submission against the regional targets.

Agenda Item	Lead Exec	Assurance Received	New/ Emerging Risks	Actions/ Comments
		to consider were shared (Elective Care, Cancer, Diagnostics, Resource, Workforce).	planning group.	Review cost pressures and investments based on quality, performance and finance. Refine performance trajectories for weekly monitoring and delivery. CIP divisional review (target 50% by the end of the financial year).
6.2 Financial Planning	KE	Draft financial plan presented. Draft submission of break-even plan to ICB on 15 th Feb 2023. Final submission 27 th March to be updated at Board of Directors.	Inflation. Pressure in the drugs budget. Patient admin funding. SLA management. 5 year re-valuation of the estate. System financial deficit and potential requirement to improve position.	Review of cost pressures. Continued engagement with ICB.
6.3 Capital Planning	KE	Capital Plan for 2023/24 and associated risks and next steps. The Trust has a capital plan that is within the confirmed allocation from the ICB. The Trust continues to have strong cash balances and internal resources are available to fund the capital programme.	Risk of overspend relating to the Cath Lab No contingency included in the plan	Cath Lab project being actively managed. The Trust is working with ICB colleagues to maximise the capital allocation available for the Trust, and mitigate risks Continuous review of risks and prioritization.
6.4 Risks and Issues		Discussion of key risks and issues.	-	-
7.1 Financial Strategy	KE	Presentation on the financial strategy of LHCH. Aims to deliver the Increasing Value objective of our over-arching strategy, 'Patients, Partnerships & Population'.	System Collaboration risk (as well as reward) Changes to financial regime. Austerity and political landscape.	Good culture and commitment enabling confidence in achieving the strategy.

Agenda Item	Lead Exec	Assurance Received	New/ Emerging Risks	Actions/ Comments
7.2 Month 10 Finance Report	KE	<p>The Trust year to date position at month 10 is a surplus of £3,480k, which is £1,540k above plan.</p> <p>The Trust remains on course to deliver its financial plan in 2022/23.</p>	Risk relating to energy costs, inflationary pressures and CIP delivery.	Risks can be mitigated this year, but pose a continued risk in the future.
7.3 Recovery Plan Update	JM	<p>Surgery financial recovery plan.</p> <p>The Surgical Division have delivered against the recovery plan proposed in Q3 22/23.</p>	<p>Theatres non-pay pressure has emerged as a new risk.</p> <p>Impact of IA.</p>	The continued delivery against this recovery plan will be reported monthly to the Finance and Performance Group and will be monitored at the Surgery Divisional Board.